Yahoo
NYSE - Nasdaq Real Time Price USD

Haemonetics Corporation (HAE)

102.75 -1.21 (-1.16%)
As of 3:24:29 PM EDT. Market Open.
Trade HAE on Coinbase
Chart Range Bar
Loading chart for HAE
  • Previous Close 103.96
  • Open 103.06
  • Bid 102.62 x 10000
  • Ask 102.83 x 10000
  • Day's Range 101.39 - 103.95
  • 52 Week Range 47.32 - 109.57
  • Volume 243,502
  • Avg. Volume 846,514
  • Market Cap (intraday) 4.675B
  • Beta (5Y Monthly) 0.52
  • PE Ratio (TTM) 49.64
  • EPS (TTM) 2.07
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 106.40

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

www.haemonetics.com

3,009

Full Time Employees

March 28

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Performance Overview

Trailing total returns as of 8/31/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

HAE
28.20%
S&P 500 (^GSPC)
12.21%

1-Year Return

HAE
88.39%
S&P 500 (^GSPC)
18.90%

3-Year Return

HAE
14.51%
S&P 500 (^GSPC)
70.41%

5-Year Return

HAE
63.75%
S&P 500 (^GSPC)
69.84%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 339.38M
Earnings 33.01M
Profit Margin 9.73%

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

0
100M
200M
300M
-5.0%
0.0%
5.0%
10.0%

Analyst Insights

View More

Analyst Price Targets

86.00 Low
106.40 Average
102.75 Current
120.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/21/2026
Analyst Baird
Rating Action Maintains
Rating Outperform
Price Action Raises
Price Target 96 -> 119

Statistics

View More

Valuation Measures

Annual
As of 8/27/2026
  • Market Cap

    4.78B

  • Enterprise Value

    5.73B

  • Trailing P/E

    50.72

  • Forward P/E

    19.96

  • PEG Ratio (5yr expected)

    1.66

  • Price/Sales (ttm)

    3.63

  • Price/Book (mrq)

    5.71

  • Enterprise Value/Revenue

    4.24

  • Enterprise Value/EBITDA

    21.18

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.12%

  • Return on Assets (ttm)

    6.60%

  • Return on Equity (ttm)

    11.20%

  • Revenue (ttm)

    1.35B

  • Net Income Avi to Common (ttm)

    96.29M

  • Diluted EPS (ttm)

    2.07

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    224.52M

  • Total Debt/Equity (mrq)

    140.26%

  • Levered Free Cash Flow (ttm)

    312.84M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

102.75 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Raising target price to $114.00

    Haemonetics Corp has an Investment Rating of HOLD; a target price of $114.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.

    Rating
    Price Target
  • Raising target price to $110.00

    Haemonetics Corp has an Investment Rating of HOLD; a target price of $110.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.

    Rating
    Price Target
  • Raising target price to $92.00

    Haemonetics Corp has an Investment Rating of HOLD; a target price of $92.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.

    Rating
    Price Target
  • Raising target price to $90.00

    Haemonetics Corp has an Investment Rating of HOLD; a target price of $90.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.

    Rating
    Price Target

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: